WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /CNW/ -- The Leukemia &
Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. today announced a
partnership to support Phase 2 development of Celator's lead product candidate
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults
with acute myeloid leukemia (AML).
Through the partnership, LLS will provide $3.7 million to support
Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus
intensive salvage therapy in adult patients less than or equal to 60 years of
age with AML in first relapse. Celator expects to start patient enrollment in
this study in the first quarter of 2009 in the United States and Canada.
The partnership between Celator and LLS is part of LLS's Therapy
Acceleration Program (TAP), which supports private sector and academic-based
projects with the goal of advancing investigational therapies with high
prospects for providing near-term benefit to patients with blood cancers.
"Celator has discovered a novel way to deliver and enhance the activity
of agents that have been the standard of care in AML for decades," said Louis
DeGennaro, Ph.D., LLS's chief scientific officer. "There have been many
attempts to improve outcomes in this patient population with little success.
The data collected on CPX-351 to date, and the enthusiasm of clinical
investigators involved in that research, suggest that Celator's approach holds
real promise to advance the treatment of AML."
"We are very pleased that The Leukemia & Lymphoma Society sees the
potential of CPX-351 and is making this substantial investment," said Scott
Jackson, chief executive officer, Celator Pharmaceuticals. "LLS has created a
well defined, streamlined process for accessing capital for promising new
blood cancer treatments. This commitment enhances our ability to further the
clinical development of CPX-351 in patients with AML."
CPX-351 represents a new approach to developing combinations of drugs in
which drug molar ratios with synergistic anti-tumor activity are encapsulated
in a drug delivery vehicle in order to maintain the desired ratio following
administration. CPX-351 has been granted orphan drug status by the U.S. Food &
Drug Administration (FDA) for the treatment of AML and is currently being
studied in a randomized trial comparing CPX-351 versus conventional cytarabine
and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated
About Acute Myeloid Leukemia (AML)
The National Cancer Institute defines AML as a quickly progressing
disease in which too many immature white blood cells (not lymphocytes) are
found in the blood and bone marrow. In 2008, the American Cancer Society's
Cancer Facts and Figures estimates 13,290 new cases of AML and 8,820 deaths.
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY,
with 68 chapters in the United States and Canada, is the world's largest
voluntary health organization dedicated to funding blood cancer research and
providing education and patient services. LLS's mission: Cure leukemia,
lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of
patients and their families. Since its founding in 1949, LLS has invested more
than $600 million in research specifically targeting leukemia, lymphoma and
myeloma. Last year alone, LLS made 6.3 million contacts with patients,
caregivers and healthcare professionals.
For more information about blood cancer, visit www.LLS.org or call LLS's
Information Resource Center (IRC), a call center staffed by master's level
social workers, nurses and health educators who provide information, support
and resources to patients and their families and caregivers. IRC information
specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to
6 p.m. ET.
Celator(R) Pharmaceuticals, Inc., with locations in Princeton, NJ, and
Vancouver, BC, is a privately held pharmaceutical company developing new and
more effective therapies to treat cancer. CombiPlex(R), the company's drug
ratio technology platform, represents a novel approach that identifies molar
ratios of drugs that will deliver a synergistic benefit, locks the desired
ratio in a drug delivery vehicle that maintains the ratio in patients with the
goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a
liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in
patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of
irinotecan:floxuridine), currently in Phase 2 in patients with colorectal
cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a
preclinical stage compound; and multiple research programs. Based on the
applications of CombiPlex, Celator is positioned to advance a broad pipeline
of combination therapies involving both previously approved and novel drug
agents. For more information, please visit the company's website at
For further information:
For further information: Andrea Greif of The Leukemia & Lymphoma
Society, +1-914-821-8958, email@example.com; or Mike Beyer, for Celator
Pharmaceuticals, Inc., +1-773-463-4211, firstname.lastname@example.org Web Site: